Pancreatic Cancer Detection Consortium

Launched by CITY OF HOPE MEDICAL CENTER · Apr 24, 2024

Keywords

ClinConnect Summary

The Pancreatic Cancer Detection Consortium is a clinical trial aimed at finding a new way to detect pancreatic cancer early and without invasive procedures. The researchers are studying a specific biological marker found in tiny particles called exosomes that carry microRNAs, which may help identify pancreatic ductal adenocarcinoma, a common type of pancreatic cancer, at stages I through IV. By using this method, they hope to improve early detection, which is crucial for better treatment outcomes.

To participate in this study, individuals must have a confirmed diagnosis of pancreatic ductal adenocarcinoma and have provided samples before starting any treatment aimed at curing the disease. The trial is open to people aged 65 to 74 and does not have gender restrictions. Participants can expect to undergo standard diagnostic procedures and may contribute to important research that could help in the fight against pancreatic cancer. It's important to note that anyone interested in joining the trial needs to give written consent to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
• • Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
• • Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)
• Exclusion Criteria:
• • Lack of written informed consent.